Topics

Orphan drug status granted to Axovant's GM1 gangliosidosis candidate

04:39 EST 19 Nov 2019 | SmartBrief

The FDA granted Axovant Gene Therapies' lead candidate AXO-AAV-GM1 orphan drug designation as a treatment for GM1 gangliosido -More

Original Article: Orphan drug status granted to Axovant's GM1 gangliosidosis candidate

NEXT ARTICLE

More From BioPortfolio on "Orphan drug status granted to Axovant's GM1 gangliosidosis candidate"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...